QGQingdong Guan

Qingdong Guan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qingdong Guan has a total of 155 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of the Novel HLA ‐B*27:03:01:02 Allele, and Confirmation of HLA ‐C*07:02:01:79 by NGS

    by Qingdong Guan, Kristin Jacobson, Aggie Gentile, Hernan Suniga

    The novel allele HLA‐B*27:03:01:02 and the confirmatory allele HLA‐C*07:02:01:79 were identified during routine HLA typing.


  • Identification of Two Novel Alleles HLA‐B*14:136 and HLA‐B*58:159 by Next‐Generation Sequencing

    by Qingdong Guan, Kristin Jacobson, Aggie Gentile, Hernan Suniga

    Two novel HLA‐B alleles, HLA‐B*14:136 and ‐B*58:159, identified by NGS during the routine HLA typing.


  • Open Access

    The Interactions of T Cells with Myeloid-Derived Suppressor Cells in Peripheral Blood Stem Cell Grafts

    by Qingdong Guan, Scott G. Gilpin, James Doerksen, Lauren Bath, Tracy Lam, Yun Li, Pascal Lambert, Donna A. Wall

    The interaction of myeloid-derived suppressor cells (MDSCs) with T cells within G-CSF-mobilized peripheral blood stem cell (PBSC) grafts in patients undergoing autologous or allogeneic hematopoietic stem cell transplantation remains to be elucidated. Through studying allo- and auto-PBSC grafts, we observed grafts containing large numbers of T cells and MDSCs with intergraft variability in their percentage and number. T cells from autologous grafts compared to allografts expressed relative higher percentages of inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, TIGIT and BTLA. Autograft T cells had decreased cell proliferation and IFN-γ secretion, which supported the possible presence of T cell exhaustion. On the contrary, graft monocytic MDSCs (M-MDSCs) expressed multiple inhibitory receptor ligands, including PD-L1, CD86, Galectin-9, HVEM and CD155. The expression of inhibitory receptor ligands on M-MDSCs was correlated with their corresponding inhibitory receptors on T cells in the grafts. Isolated M-MDSCs had the ability to suppress T cell proliferation and IFN-γ secretion and/or promote Treg expansion. Blocking the PD-L1-PD-1 signaling pathway partially reversed the functions of M-MDSCs. Taken together, our data indicated that T cells and M-MDSCs in PBSC grafts express complementary inhibitory receptor–ligand pairing, which may impact the quality of immune recovery and clinical outcome post transplantation.


  • Manufacturing autologous myoblast for regenerative medicine applications

    by Matthew Lee-Wing, David Szwajcer, Anthony Lockwood, Alanna Flynn, Karla Anjos, Marie Tulloch, Angeline Giftakis, Qingdong Guan

    Background: Autologous myoblasts have been tested in the treatment of muscle-related diseases. However, the standardization of manufacturing myoblasts is still not established. Here we report a flask and animal-free medium-based method of manufacturing clinical-grade myoblast together with establishing releasing criteria for myoblast products under Good Manufacturing Practice (GMP). Methods: Quadriceps muscle biopsy samples were donated from three patients with myogenic ptosis. After biopsy samples were digested through enzymatic dissociation, the cells were grown in T175 flasks (passage 0) and hyperflasks (passage 1) in the animal-free SkGMTM-2 skeletal muscle cell growth medium containing 5% human platelet lysate for 15–17 days. The harvested cells were released based on cell morphology, cell dose, viability, sterility, endotoxin, mycoplasma and immunophenotype. Myotube differentiation was also evaluated. Results: 400 to 500 million myoblast cells were manufactured within 15 to 17 days by the end of passage 1, which met pre-determined releasing criteria. The manufactured myoblast cells could differentiate and fuse into myotubes in vitro, with the possible trend that the donor age may impact the differentiation ability of myoblasts. Conclusions: The present study establishes a flask-based method of manufacturing myoblast in the animal-free medium together with releasing criteria, which is simple, robust, inexpensive and easily reproducible. This study will serve as the validation for a planned phase 1 clinical trial to assess the use of autologous myoblast transplants for the treatment of myogenic ptosis and other myogenic diseases.


  • Open Access

    Interactions between Gut Microbiota and Immunomodulatory Cells in Rheumatoid Arthritis

    by Huihui Xu, Hongyan Zhao, Danping Fan, Meijie Liu, Jinfeng Cao, Ya Xia, Dahong Ju, Cheng Xiao, Qingdong Guan

    Rheumatoid arthritis (RA) is one of the most common autoimmune diseases caused by abnormal immune activation and immune tolerance. Immunomodulatory cells (ICs) play a critical role in the maintenance and homeostasis of normal immune function and in the pathogenesis of RA. The human gastrointestinal tract is inhabited by trillions of commensal microbiota on the mucosal surface that play a fundamental role in the induction, maintenance, and function of the host immune system. Gut microbiota dysbiosis can impact both the local and systemic immune systems and further contribute to various diseases, such as RA. The neighbouring intestinal ICs located in distinct intestinal mucosa may be the most likely intermediary by which the gut microbiota can affect the occurrence and development of RA. However, the reciprocal interaction between the components of the gut microbiota and their microbial metabolites with distinct ICs and how this interaction may impact the development of RA are not well studied. Therefore, a better understanding of the gut microbiota, ICs, and their interactions might improve our knowledge of the mechanisms by which the gut microbiota contribute to RA and facilitate the further development of novel therapeutic approaches. In this review, we have summarized the roles of the gut microbiota in the immunopathogenesis of RA, especially the interactions between the gut microbiota and ICs, and further discussed the strategies for treating RA by targeting/regulating the gut microbiota.


  • Top Cited Papers
    Open Access

    A Comprehensive Review and Update on the Pathogenesis of Inflammatory Bowel Disease

    by Qingdong Guan

    Inflammatory bowel disease (IBD) is a chronic and life-threating inflammatory disease of gastroenteric tissue characterized by episodes of intestinal inflammation. The pathogenesis of IBD is complex. Recent studies have greatly improved our knowledge of the pathophysiology of IBD, leading to great advances in the treatment as well as diagnosis of IBD. In this review, we have systemically reviewed the pathogenesis of IBD and highlighted recent advances in host genetic factors, gut microbiota, and environmental factors and, especially, in abnormal innate and adaptive immune responses and their interactions, which may hold the keys to identify novel predictive or prognostic biomarkers and develop new therapies.


  • Open Access

    Sustained Suppression of IL-18 by Employing a Vaccine Ameliorates Intestinal Inflammation in TNBS-Induced Murine Colitis

    by Qingdong Guan, Richard Warrington, Sem Moreno, Gefei Qing, Carolyn Weiss, Zhikang Peng

    To develop IL-18 peptide-based virus-like particle vaccines that elicit autoantibodies against IL-18 and to evaluate the in vivo effects of the vaccines in murine colitis. Recombinant IL-18 vaccines were constructed, and the effects of the vaccines were evaluated in trinitrobenzene sulfonic acid-induced acute and chronic colitis in mice. Two murine IL-18 peptide-based vaccines (A and D) were developed, which induced relative long-lasting specific antibodies against IL-18. Vaccine-immunized mouse antisera could partially block IL-18-induced IFN-γ production in vitro. Mice receiving vaccine D, not vaccine A, had a significant decrease in intestinal inflammation, collagen deposition and pro-inflammatory cytokine levels in colon tissue. IL-18 vaccine may provide a potential therapeutic approach in the treatment of Crohn's disease.


  • Myeloid‐derived suppressor cells: Roles and relations with Th2, Th17, and Treg cells in asthma

    by Qingdong Guan, Bin Yang, Richard J. Warrington, Steven Mink, Chrystyna Kalicinsky, Allan B. Becker, Elinor Simons, Zhikang Peng


  • Expression and function of phosphoinositide 3‐kinase delta in mesenchymal stromal cells from normal and leukaemic bone marrow

    by Ahmed Y. Ali, Qingdong Guan, Xun Wu, Sen Hou, Versha Banerji, James B. Johnston, Donna Wall, David Szwajcer, Spencer B. Gibson, Aaron J. Marshall

    Within lymphoid tissues, chronic lymphocytic leukaemia (CLL) cells interact with mesenchymal stromal cells (MSC). Inhibitors of phosphoinositide 3‐kinase delta (PI3Kδ) cause release of CLL cells from lymphoid tissues into blood. PI3Kδ inhibitors are thought to target only CLL and other immune cells because PI3Kδ expression is restricted to haematopoietic cells. We found that PI3Kδ is unexpectedly expressed in primary MSC derived from CLL patients and healthy donors. PI3Kδ inhibition in MSC using idelalisib or duvelisib significantly reduced their ability to support CLL migration and adhesion. These observations provide the first evidence that PI3Kδ is expressed and functional in CLL MSC.